This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
by Zacks Equity Research
Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
by Zacks Equity Research
Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.
Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B
by Zacks Equity Research
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.
Is Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Absci Corporation (ABSI) and Novo Nordisk (NVO) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, AbbVie and Novartis
by Zacks Equity Research
Eli Lilly, Novo Nordisk, AbbVie and Novartis have been highlighted in this Industry Outlook article.
3 Reasons Growth Investors Will Love Novo Nordisk (NVO)
by Zacks Equity Research
Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.
Bristol-Myers (BMY) Q4 Earnings & Sales Beat, Stock Gains
by Zacks Equity Research
Bristol-Myers' (BMY) fourth-quarter 2023 earnings and sales surpass estimates as Reblozyl and Revlimid outperform. Shares rise on the same.
Pharma Stock Roundup: PFE, MRK, NVO & SNY's Q4 Earnings, FDA Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
4 Large Drug Stocks Trying to Survive the Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
by Zacks Equity Research
Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.
Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
by Zacks Equity Research
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
Private-Sector Payrolls Declined More Than Expected
by Zacks Equity Research
Private-Sector Payrolls Declined More Than Expected
Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag
by Zacks Equity Research
Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.
ADP Cools to 107K Private-Sector Jobs; BA, NVO Beat in Q4
by Mark Vickery
We've now spent a full six months sub-200K private-sector job gains per month.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk (NVO) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected fourth-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
The Zacks Analyst Blog Highlights Apple, Visa, Novo Nordisk, PepsiCo and CrowdStrike Holdings
by Zacks Equity Research
Apple, Visa, Novo Nordisk, PepsiCo and CrowdStrike Holdings are part of the Zacks Analyst Blog.
Here's How Much a $1000 Investment in Novo Nordisk Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Best Growth Stocks to Buy for January 31st
by Zacks Equity Research
TX, POWL and NVO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 31, 2024.
Big Earnings Afternoon: Microsoft, Alphabet, Starbucks & More
by Mark Vickery
Microsoft, Google-parent Alphabet, Mondelez and Skyworks all topped earnings expectations.
Top Stock Reports for Apple, Visa & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Visa Inc. (V) and Novo Nordisk A/S (NVO).
Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump
by Zacks Equity Research
Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.
Wall Street Analysts See Novo Nordisk (NVO) as a Buy: Should You Invest?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK
by Ahan Chakraborty
Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.